Tilray Posts Record Revenue Highs After BrewDog Acquisition but Shares Lag Cannabis Sector Rebound

The Quick Take

• Tilray Brands reported record Q4 FY2026 revenue driven by the BrewDog acquisition and diversified segment growth.
• Despite revenue records, TLRY shares lag the broader cannabis sector recovery, suggesting valuation disconnect.
• The BrewDog beer brand integration adds recurring consumer revenue that partially offsets cannabis regulatory uncertainty.
• Analyst price targets suggest significant upside if cannabis legalization tailwinds materialize in the US market.

Tilray Brands' record Q4 FY2026 revenue — boosted by its BrewDog beer brand acquisition and diversified segment contributions — has not translated into proportionate share price appreciation, creating what analysts describe as a meaningful valuation discount relative to underlying business fundamentals. The company's transformation from a pure-play cannabis producer into a diversified beverage and wellness conglomerate represents a bet on building revenue floors through non-cannabis streams while waiting for US legalization to catalyze the core business.

The BrewDog acquisition is central to the investment thesis. BrewDog's craft beer operations provide Tilray with legitimate consumer goods revenue, distribution infrastructure, and brand equity that insulate the company from the volatility of cannabis-only operators. While cannabis revenue remains the growth engine — particularly through medical cannabis in Germany and recreational in Canada — the beer operations provide recurring, predictable cash flow. However, integration costs and BrewDog's own brand controversies have weighed on near-term margins.

The undervaluation argument rests on regulatory optionality: any progress on US federal cannabis rescheduling or state-level legalization would act as a significant multiple expander for TLRY, as the company's existing US distribution network and brand recognition would translate into rapid revenue capture. The risk is timing — Tilray has been making this argument for years, and regulatory catalysts have consistently disappointed. Watch the US Drug Enforcement Administration's cannabis scheduling review timeline and any Senate momentum on legalization as the key binary events for the TLRY thesis.

Synthesized from 1 source.